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Duke Clinical Research Institute and Division of Gastroenterology, Duke University Medical Center, P.O. Box 17969, Durham, NC 27715, USACurrent therapy for chronic hepatitis C virus (HCV) infection is eﬀective in less than 50% of genotype 1-infected
patients. Antiviral agents speciﬁcally targeting either the HCV protease or polymerase, or other targets, are now in clinical
development. In general, direct antivirals are potent inhibitors of HCV replication and can result in rapid declines in serum
HCV RNA levels. Yet these agents drive selection pressure for mutant viruses that can reduce susceptibility to any given
drug. Using pegylated interferon (PEG-IFN) and ribavirin (RBV) in combination with direct antivirals can suppress viral
breakthrough and increase the likelihood of sustained virologic response. Direct antivirals also result in adverse events in a
proportion of patients, adding to concerns of tolerability that exist with PEG-IFN and RBV. Direct antivirals are very
likely to become an integral part of treatment within the next decade, and already their use in clinical trials has raised
important issues related to duration of treatment, early stopping rules, retreatment of previously treated patients, and
how or when direct antivirals should be combined. Here, we provide current information regarding the eﬀectiveness of
direct antivirals in treating chronic HCV infection and discuss the key questions and challenges now facing the ﬁeld.
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(PEG-IFN) combined with ribavirin (RBV) for suitable
patients with chronic hepatitis C virus (HCV) infection
can eradicate virus permanently in those patients who0168-8278/$34.00  2008 European Association for the Study of the Liver.
doi:10.1016/j.jhep.2008.10.011
Associate Editor: M. Colombo
q Dr. McHutchison is a consultant for and received grants from
Anadys, Coley Pharmaceutical Group, First Gilead, GlaxoSmith
Kline, Human Genome Sciences, Idenix Pharmaceuticals, Intarcia,
Novartis, Pharmasset, Pﬁzer, Roche, Schering-Plough, Valeant Phar-
maceuticals, Vertex Pharmaceuticals, Virochem and Wyeth. He
received grants from Biolex, Globe Immune, Idera, Medtronics, Salix
Pharmaceuticals, and Sanoﬁ-Aventis. He is also a consultant for
Abbott, Biolex, Epiphany Biosciences, InterMune Pharmaceuticals,
Juvaris, National Genetics Institute, Peregrine, and United Therapeu-
tics.
* Corresponding author.
E-mail address: mchut001@mc.duke.edu (J.G. McHutchison).achieve a sustained virologic response (SVR). However,
this treatment is only eﬀective in approximately 40% of
patients with genotype 1 infection, the most common
genotype in Europe and North America [1]. Therapy is
also costly and frequently associated with side eﬀects
that to a variable degree limit eligibility for, and compli-
ance with, therapy. For these reasons, alternative, more
eﬀective treatment strategies that would be more
broadly available and applicable to patients with
chronic HCV must be developed.
While many new compounds interacting with a vari-
ety of targets are currently in development (Fig. 1) [2,3],
in this review we focus only on the development of the
HCV protease and polymerase inhibitors. These agents
are currently the most promising in clinical develop-
ment. Both classes are potent inhibitors of viral replica-
tion, and in clinical trials several candidates have
signiﬁcantly enhanced response rates compared with
our current regimen. However, certain principles andPublished by Elsevier B.V. All rights reserved.
Fig. 1. Speciﬁcally targeted antivirals currently in development. Most targets known to the authors are shown for completeness. While the list is
incomplete, more than 50 clinical trials are currently underway in chronic hepatitis C patients. The direct antivirals active against the HCV protease and
polymerase are depicted as separate groups, and are an area of intense interest and drug development with many ‘‘ﬁrst” and subsequent generation
compounds in a variety of earlier and latter stage clinical development.
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suppressing resistance must now be addressed to move
the clinical trial framework forward successfully. While
all direct antiviral agents and data relating to them can-
not be covered in this review, we highlight speciﬁc exam-
ples and issues related to their use by addressing the
following key and clinically relevant questions.2. How eﬀective are HCV protease and polymerase
inhibitors?
Inhibitors of the NS3/4a protease have been the most
extensively studied direct antivirals to date, and two
such agents, the peptidomimetic inhibitors telaprevir
and boceprevir, have now progressed to phase 3 clinical
trials. In genotype 1, treatment-naı¨ve HCV patients,
telaprevir in combination with PEG-IFN and RBV
can result in SVR rates (deﬁned as HCV RNA negativ-
ity 24 weeks post therapy) as high as 68% [4]. Similarly,
in genotype 1, treatment-naı¨ve HCV patients, the rate of
HCV RNA negativity 12 weeks post therapy (an earlier
and accurate surrogate of SVR), with boceprevir has
been as high as 74% [5].
Inhibitors of the HCV NS5B RNA-dependent RNA
polymerase (RdRp) include nucleos(t)ide inhibitors
and non-nucleos(t)ide inhibitors. A total of at least ﬁve
diﬀerent target sites within the HCV polymerase havebeen identiﬁed. R1626, a prodrug of a cytidine analog,
is a nucleoside inhibitor currently in phase 2 develop-
ment. When used in combination with PEG-IFN and
RBV for 4 weeks, the mean maximal viral load reduc-
tion from baseline was 5.2 log10 IU/mL [6]. R7128,
another cytidine analog prodrug, has shown a similar
mean reduction in HCV RNA, 5 log10 IU/mL, when
used with PEG-IFN and RBV for 4 weeks in treat-
ment-naı¨ve genotype 1 patients [7].
Non-nucleoside inhibitors target the NS5B RdRp at
a site separate from the enzyme’s catalytic center. In a
phase 1 study, treatment with the non-nucleoside inhib-
itor VCH-759 resulted in mean maximal decreases in
HCV RNA of up to 2.5 log10 IU/mL [8], and the drug
has progressed to phase 2 studies.
Several other protease and polymerase inhibitors are
in clinical development, and it is likely that many of
them will also display rapid, highly eﬀective and eﬃ-
cient, robust suppression of HCV replication.3. Can these antivirals be given as monotherapy, or can we
dispense with PEG-IFN?
Currently interferon remains a crucial backbone for
HCV therapy. When the ﬁrst direct antivirals entered
clinical trials with HCV-infected patients, the ‘‘hope”
was that they might replace PEG-IFN and/or RBV
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ever, early clinical trials indicated that monotherapy
with direct antivirals selects for resistance mutations
within a week, and as such, they cannot be given eﬀec-
tively alone.
BILN-2061, the ﬁrst NS34a protease inhibitor to
enter clinical trials, produced a greater than 2-
log10 IU/mL reduction in HCV RNA after only 2 days
in HCV genotype 1-infected patients [9]. Yet early
in vitro studies revealed the worrying concern of emer-
gence of drug resistance to BILN-2061 [10], which is no
longer in development because of cardiac toxicity in
laboratory animals. In a separate phase 1b study exam-
ining telaprevir monotherapy in genotype 1 patients,
those who received 750 mg of drug every 8 h for 2
weeks had a median maximal viral load reduction of
4.4 log10 IU/mL [11]. However, during the second week
of treatment, virologic breakthrough, as evidenced by a
rebound in HCV RNA, was noted in a signiﬁcant
number of patients who received lower doses. Subse-
quent clinical trials have established that adding
PEG-IFN in combination with telaprevir increases
HCV RNA suppression and reduces the emergence of
resistance. In a small trial conducted in genotype 1-
infected patients, combination therapy with telaprevir
and PEG-IFN for 14 days led to a greater median
HCV RNA reduction (5.5 log10 IU/mL) than either
telaprevir (4.0 log10 IU/mL) or PEG-IFN (1.0
log10 IU/mL) alone [12]. Viral sequence analysis identi-
ﬁed resistance mutations in fewer (2 of 7) patients
receiving combination therapy versus 7 of 8 receiving
telaprevir monotherapy.
Similar to telaprevir, the protease inhibitor bocepre-
vir also results in more robust reductions in HCV
RNA when used in combination with PEG-IFN. In a
phase 1b crossover study, patients who received
400 mg of boceprevir tid and PEG-IFN had a mean
maximum HCV RNA reduction of 2.88 log10 IU/mL,
compared with 1.61 log10 IU/mL for those who received
boceprevir alone at the same dose [13].
In contrast to protease inhibitors, nucleoside poly-
merase inhibitors theoretically have a higher genetic bar-
rier to resistance. Unfortunately, those examined thus
far in larger trials induce only modest viral suppression.
Valopicitabine, a nucleoside analog of 20-C-methylcyti-
dine, has a documented up to 1.2 log10 IU/mL HCV
RNA reduction in genotype 1-infected patients. But
when used in combination with PEG-IFN, valopicita-
bine has a dose-dependent additive antiviral eﬀect [14].
The cytidine nucleoside analog R7128 has been
reported to induce a mean maximum decline of 2.72
log10 IU/mL at 1500 mg bid for 14 days in genotype 1
prior nonresponders [15]. Yet in an ongoing trial of
treatment-naı¨ve, HCV genotype 1 patients, combining
R7128 1500 mg bid with PEG-IFN and RBV has been
reported to lead to a greater reduction in HCVRNA—5 log10 IU/mL at 4 weeks—similar to that
observed with the current protease inhibitor trials [7].
Compared with the nucleoside inhibitors, both sub-
optimal antiviral suppression and drug resistance have
so far been signiﬁcant issues for non-nucleoside poly-
merase inhibitors. The inhibitor HCV-796 targets the
non-nucleoside allosteric D site, in the hinge of the
RdRp. In a phase 1b study, the highest dose of HCV-
796 was reported to be associated with a peak mean
HCV RNA reduction of 1.4 log10 IU/mL [16]. Unfortu-
nately, most patients relapsed after a few days of ther-
apy. However, in a phase 2 trial in which HCV
genotype 1 and non-1 infected patients received combi-
nation PEG-IFN and HCV-796 for 14 days, the HCV
RNA level reduction was 3.3–3.5 log10 IU/mL in the
combination groups, and no relapse caused by resistance
was observed during therapy [17].
There may be several important factors that contrib-
ute to suboptimal viral suppression by a direct antiviral.
For example, poor drug bioavailability and other phar-
macokinetic factors could limit the amount of drug
delivered to infected hepatoctyes. Nonetheless, current
clinical data support a trial model of including PEG-
IFN in combination with individual antivirals and
developing a clear understanding of the reasons any
drug is associated with submaximal viral suppression.4. Can the addition of a direct antiviral allow us to
dispense with ribavirin?
Experience with both protease and polymerase inhib-
itors suggests that ribavirin will remain an essential com-
ponent of HCV therapy for the foreseeable future. The
phase 2 PROVE2 study of telaprevir included four treat-
ment groups, two of which included triple therapy with
PEG-IFN and RBV, one standard of care, and the
remaining arm only telaprevir and PEG-IFN. The tela-
previr and PEG-IFN arm had a higher virological
breakthrough rate, 26%, versus 2% in the triple therapy
arms [4]. RBV therefore has an important eﬀect in lim-
iting the emergence of resistant variants. Within this
study, two groups received identical regimens except
for the presence or absence of ribavirin. Between those
groups, the triple therapy regimen resulted in an SVR
of 62% and a relapse rate of 29%, whereas double ther-
apy without ribavirin demonstrated a lower SVR rate of
36% and a signiﬁcantly higher relapse rate of 48% (Table
1). The value of RBV therefore extends beyond prevent-
ing resistance, to also limiting relapse.
Additionally, a phase 2 study of valopicitabine in
genotype 1 prior nonresponder patients included three
study arms: valopicitabine and PEG-IFN; valopicita-
bine, PEG-IFN, and RBV; and PEG-IFN and RBV.
At day 36, 23% of patients treated with triple combina-
tion therapy were HCV RNA negative, compared with
Table 1
Virologic responses to telaprevir- or boceprevir-based treatment regimens
RVR (%) EVR (%) SVR12 (%) SVR24 (%) Relapse (%)
PEG-IFN + RBV (control arms)
PROVE1 11 45 41 23
PROVE2 13 41 48 20
SPRINT-1 38
Telaprevir + PEG-IFN, 12 weeks
PROVE2 51 62 36 48
Telaprevir + PEG-IFN + RBV
12 weeks
PROVE1 59 71 35 33
PROVE2 80 79 62 29
24 weeksa
PROVE1 81 68 61 2
PROVE2 69 73 68 14
48 weeksa
PROVE1 81 80 67 6
Boceprevir + PEG-IFN + RBV (SPRINT-1)
28 weeks
Inductionb 56
No induction 55
48 weeks
Inductionb 74
No induction 66
EVR, early virologic response (12 weeks); PEG-IFN, pegylated interferon; RBV, ribavirin; RVR, rapid virologic response (4 weeks); SVR12,
sustained virologic response week 12 post-treatment; SVR24, sustained virologic response week 24 post-treatment.
a Telaprevir was administered only during the ﬁrst 12 weeks of therapy [4,19,23].
b Boceprevir was not administered for the ﬁrst 4 weeks of therapy [5].
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14% of patients treated with valopicitabine and PEG-
IFN [18].
And ﬁnally, in a third phase 2 study, dual therapy
with PEG-IFN and the nucleoside inhibitor R1626 at
1500 mg bid resulted in a week 4 HCV RNA undetect-
able response rate of 29%, compared with 74% for triple
therapy including ribavirin [6]. At week 4, the mean
HCV RNA decrease from baseline for the dual therapy
group was 3.6 log10 IU/mL, versus 5.2 log10 IU/mL for
triple therapy. The diﬀerence of 1.6 log10 IU/mL again
suggests that RBV has a synergistic eﬀect in terms of
antiviral eﬃcacy for both protease and polymerase
inhibitors, driving higher on-treatment and sustained
response rates and limiting resistance.
In the future, it may be theoretically possible to com-
bine protease and polymerase inhibitors, or other tar-
geted drugs, and dispense with ribavirin, but for now,
ribavirin seems an essential component of these newer
HCV therapeutic regimens in development.5. Are there additional side eﬀects when adding a direct
antiviral to PEG-IFN and RBV therapy?
In most trials conducted to date, combining an oral
antiviral with PEG-IFN and RBV has increased thelikelihood of side eﬀects and treatment discontinuation.
In the PROVE1 and PROVE2 studies of telaprevir, gas-
trointestinal events, skin rashes, and anemia were more
frequent in the triple therapy arms compared with PEG-
IFN and RBV alone [4,19]. In PROVE1, the discontin-
uation rate in the ﬁrst 12 weeks with triple therapy was
18%, versus 4% with PEG-IFN and RBV. In the phase 2
studies of boceprevir, rates of anemia and ‘‘dysgeusia”
were higher with triple therapy than with standard ther-
apy, as were discontinuation rates (26–28% vs. 14%)
[20,21].
For the nucleoside inhibitor R1626, dose-limiting
gastrointestinal adverse eﬀects and mild to moderate
reversible leukopenia have been noted with mono-
therapy [22]. In combination with PEG-IFN, further
signiﬁcant hematologic toxicity has been observed.
The rate of grade 4 neutropenia was 78% when
R1626 was administered at a dose of 3000 mg bid with
PEG-IFN. Even at lower doses of R1626, the rates of
grade 4 neutropenia were 42–52%. Thirty-nine percent
of patients treated with R1626 and PEG-IFN therapy
also experienced grade 3 or 4 anemia. Most of the
hematologic toxicities reversed upon removal of
R1626, despite continuation with PEG-IFN. Gastroin-
testinal adverse events and rash are also more common
with R1626 plus PEG-IFN than with PEG-IFN alone
[6].
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ated in combination with PEG-IFN and RBV. In an
ongoing study, albeit with a small sample size, grade
3/4 hematological toxicity has been rare, with rates sim-
ilar to treatment with PEG-IFN and RBV. Headache,
fatigue, and chills have been more common than with
control, yet all events have been categorized as mild [7].
Clinical development for the polymerase inhibitors
valopicitabine and HCV-796 have both been placed on
hold because of concerns regarding toxicity: gastrointes-
tinal toxicities (nausea, vomiting and diarrhea) for valo-
picitabine, and liver toxicity for HCV-796.
Therefore, in all early phase clinical trials of direct
antivirals, management plans which incorporate careful
evaluation of diﬀerences in adverse events will be critical
to avoid exposing patients to potential serious toxicities
and to develop an early and accurate evaluation of the
tolerability of new compounds.6. What is the value of a lead-in strategy with PEG-IFN
and RBV?
A lead-in phase could accurately discriminate PEG-
IFN andRBV responders and nonresponders, and reduc-
ing viral burden prior to initiating a direct antiviral could
theoretically minimize or at least reduce the development
of drug resistant variants. Only one such study has
addressed this to date. The SPRINT-1 trial of boceprevir
in HCV genotype 1 naive patients included study arms
that received 4 weeks of PEG-IFN plus RBV followed
by the addition of boceprevir, 800 mg tid, for an addi-
tional 24 or 44 weeks. Preliminary data suggest patients
who received 28 weeks of therapy had an SVR rate of
56%, which is similar to the rate of 55% for patients with-
out the lead-in [5]. Among patients who received 48weeks
of therapy, there did appear to be some beneﬁt of the lead-
in strategy: SVR12 rates were 74%versus 64% for patients
with and without a lead-in phase. However, these results
should be interpreted with some caution, as the sample
size is relatively small.
It is therefore unclear at this stage whether a lead-in
strategy will be eﬀective with these or other antivirals
or suitable for all patient groups. Also unanswered is
what would theoretically be the most eﬀective length
of treatment in a lead-in strategy (for example 1, 2, 4,
6, or 8 weeks, most of which have not been tested)
and what duration of triple therapy is then required
for consolidation therapy?7. By adding a direct antiviral, can the duration of therapy
be shortened?
As described above, it appears that for boceprevir, 48
weeks of therapy may be needed to maximize rates ofSVR. For telaprevir, results from PROVE1 suggest 24
weeks of therapy may be suﬃcient. In PROVE1, the
group that received triple therapy for 12 weeks followed
by PEG-IFN plus RBV alone for an additional 12 weeks
had an overall SVR of 61%, comparable to the SVR of
67% seen with triple therapy for 12 weeks followed by
PEG-IFN plus RBV for an additional 36 weeks
[19,23]. In PROVE2, patients who received triple ther-
apy for 12 weeks followed by 12 weeks of PEG-IFN
and RBV had an SVR of 68%. Those who received only
12 weeks of triple therapy had an SVR of 62%, which
again is comparable, except the rate of relapse was
higher in the 12-week group (29%) versus the 24-week
group (14%) [4].
Clinical trials of polymerase inhibitors have not yet
addressed duration of combination therapy to the same
extent as those with protease inhibitors have. Given the
potential observed diﬀerences between boceprevir and
telaprevir regarding duration of treatment, it may be
that optimal duration will need to be evaluated for
each antiviral in direct comparative trials. Also, these
diﬀerent duration strategies may not apply equally to
patients who have previously not responded or
relapsed to prior therapy with IFN and RBV based
regimens. These issues will need to be addressed care-
fully in subsequent clinical trials in these patient
populations.8. What is the observed early virologic response with
direct antivirals, and how does this translate into diﬀerent
or similar stopping rules?
With telaprevir, suppression of HCV occurs early,
and in the PROVE1 study rates of week 4 undetectabil-
ity (rapid virologic response, RVR), and week 12
response (early virologic response, EVR), exceeded the
rates of SVR. Among patients who received triple ther-
apy for 12 weeks followed by either 12 or 36 weeks of
PEG-IFN plus RBV, the rate of RVR was 81%, EVR
was 74%, and SVR was 63% [19,23]. In PROVE2, rates
of virologic response were more consistent over time,
and the study arm that received 12 weeks triple therapy
followed by 12 weeks PEG-IFN plus RBV had an RVR
of 69%, an EVR of 73%, and an SVR of 68% [4].
With boceprevir, the eﬀect of rapid virologic response
is less clear. In SPRINT-1, in the non-lead-in arms, viro-
logical response increased from an RVR of 37% to a 12-
week SVR of 55% [20]. However, among patients who
received the lead-in and achieved RVR, SVR was 82%
with the 28-week regimen and SVR12 was 92% with
the 48-week regimen [5]. The deﬁnition of RVR in this
trial was also diﬀerent; the timepoint for RVR assess-
ment was after 4 weeks of triple therapy; by which stage
patients in the ‘‘lead-in” arms had received 8 weeks of
PEG-IFN and RBV.
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early virologic response may be predictive of SVR with
PEG-IFN and RBV, at this time it seems premature to
develop solid accurate stopping rules for any given
new antiviral, and rules developed for one drug regimen
may not apply to another. Additionally, whether a
response can be predicted earlier, for example, within
the ﬁrst few days or a week of treatment, needs to be
fully explored utilizing modeling techniques in larger
data sets. It will also be necessary to conﬁrm in fol-
low-up studies that SVR rates 24 weeks post-treatment
translate into long-term viral eradication and that late
relapse does not occur.Fig. 2. In vitro resistance to protease (A) and polymerase (B) inhibitors.
The list does not contain all inhibitors or identiﬁed variants but highlights
variants identiﬁed for more than one drug (for summaries see Kieﬀer
et al., 2007 [25] and Gilden, 2008 [29]). Cross resistance may be expected
to limit the eﬃcacy of retreating nonresponders or relapsers with
antivirals of the same class, as depicted.9. Clinically, how common is virologic resistance?
In vitro analyses have shown that resistance muta-
tions develop in the NS5B gene in response to poly-
merase inhibitors and in the NS3 gene in response to
protease inhibitors, as expected with HCV’s high viral
replication rate, quasispecies diversity, and error-prone
reverse transcriptase. Preliminary data analyses from
the telapravir clinical development program also sug-
gest that virologic breakthrough is associated, in gen-
eral terms, with lower trough serum levels of both
telaprevir and PEG-IFN [11,24]. Hence, promoting
and evaluating adherence to therapy with the goals of
optimizing pharmacokinetics and suppressing resis-
tance will become important aspects of all clinical trial
programs involving direct antivirals. In addition, the
eﬀect of suboptimal adherence on viral resistance and
breakthrough will also need to be evaluated in detail.
To date, in vivo resistance has been most extensively
studied with telaprevir. A phase 1b study of 16 treat-
ment-naı¨ve, genotype 1 patients that compared telapre-
vir monotherapy with telaprevir plus PEG-IFN
included a detailed kinetic analysis of viral variants
over 14 days of treatment [25]. Of 8 patients who
received telaprevir alone, 4 experienced HCV RNA
rebound, which was detected in 3 patients at day 8,
and in the fourth at day 12. Among these 4 patients,
virus isolated at day 4 was mostly wild-type but also
contained low levels (5–20%) of V36A/M, R155K/T,
and A156V/T single mutants, which were ultimately
replaced by high-level resistant double mutants (36/
155). Four patients who received telaprevir mono-
therapy experienced a continuous decline in HCV
RNA. Two of them had sequence data available for
days 8 and 12, and both had resistant variants in spite
of the decline. Thus, the presence of resistance variants
alone does not necessarily indicate failure of therapy.
Genotypic resistance, as detected by sequence analyses,
appears to be separate from phenotypic or clinical
resistance, in which HCV RNA increases after an ini-
tial decline.A major concern is that continued monotherapy
drives the selection of more resistant variants, with pro-
gressive accumulation of mutations. Based on pheno-
typic characterization of many of the substitutions,
V36A/M or T54A confer less than eightfold resistance
to telaprevir. However, variants with double substitu-
tions at Val36 plus Thr54 have approximately 20-fold
resistance to telaprevir, and variants with double substi-
tutions at Val36 plus Arg155 or Ala156 have >40-fold
resistance [26]. Even among single mutants, there can
be a substantial diﬀerence in sensitivity to drug com-
pared with wild-type virus. Some variants have a similar
sensitivity to telaprevir as wild-type, but others can be
more than 10,000-fold resistant [27]. Whether this pre-
dicted in vitro reduced sensitivity results in signiﬁcant
reduced eﬃcacy for this drug and other active com-
pounds in this class remains to be determined.
Finally, in vitro studies of various protease inhibitors
have identiﬁed variants cross-resistant to both bocepre-
vir and telaprevir, suggesting a class eﬀect (Fig. 2)
[25,28]. The selection of these variants has complicated
monotherapy with both drugs independently in vivo,
allowing the prediction that telaprevir would not be suit-
able as salvage therapy for boceprevir resistance, or vice
versa. These crucial repeat exposure experiments have
not yet been performed but can be expected to demon-
strate the rapid development of the same drug resistant
variants. Although not yet characterized in vivo, several
mutations to polymerase inhibitors—especially non-
nucleoside inhibitors—have been described [29]. As
resistant mutations are further observed and analyzed,
of interest is whether other members of this class—
nucleoside analog, non-nucleoside inhibitors, thumb
inhibitors, or allosteric binding site inhibitors—will
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ther, the role of polymerase inhibitors in treating vari-
ants resistant to protease inhibitors and vice versa will
need to be explored, sooner rather than later.10. What are the consequences of resistance, and how can
they be curtailed?
Given that antivirals have only been used in trials, the
long-term consequences can only be speculated on, but
resistance can hopefully be curtailed by using a multi-
ple-target approach.
With respect to treatment outcome, there is evidence
that some patients who experience viral breakthrough
during telaprevir monotherapy can subsequently respond
to standard therapy with PEG-IFN plus RBV, although
only a small number of patients have been studied thus
far, and a minority of them went on to achieve undetect-
able HCV RNA at week 12 after standard therapy [25].
Drug resistant variants also remain sensitive to IFN
in vitro, supporting these clinical observations.
In vivo, PEG-IFN appears to abrogate the prolifera-
tion of resistant variants. In the Kieﬀer et al study [25]
comparing telaprevir monotherapy with telaprevir and
PEG-IFN, of the 8 patients who received PEG-IFN
and telaprevir, 6 had a continuous decline in HCV
RNA, with only wild-type virus detected at day 15.
One patient had HCV RNA <10 IU/mL at day 13,
which rose to <30 IU/mL at day 15. This patient had
wild-type virus at day 4, and the high-level resistant
mutant A156T was detected at day 8. Yet after subse-
quent treatment with standard therapy, this patient
was HCV RNA negative at week 12 post-treatment, as
were the remaining 7 in the treatment group. RBV also
appears to be important in suppressing viral break-
through, as adding it to combination therapy with tela-
previr and PEG-IFN reduces virological breakthrough
rates from 26% to 2% [4].
Whether viral variants are archived is not clear, and if
so, the long-term clinical consequences are unknown.
After telaprevir monotherapy is ceased, in the absence
of selective pressure the majority of resistant variants
are replaced by wild-type virus within 3–7 months [30].
Yet several issues remain to be addressed: does the rep-
licative ﬁtness of variants change over time, will the
presence of variants inﬂuence the rate of disease pro-
gression, and will patients who do not respond to one
antiviral respond to subsequent therapy with drugs of
the same or diﬀerent classes?11. How should resistance testing be standardized?
Experience with telaprevir suggests that the probabil-
ity of detecting resistance mutations depends upon themethod of detection and its sensitivity. For example,
in a serum sample from a patient at day 2 of telaprevir
dosing, clonal sequencing analysis detected the variant
V36M at a frequency of about 5%, while the population
sequencing analysis revealed no mutants, only wild-type
virus.
Thus, the method of testing, frequency of testing, and
deﬁnitions of outcomes all inﬂuence the ability to detect
and interpret development of resistance to any given
drug. Yet none of these factors is currently standard-
ized, making it diﬃcult to fully understand the preva-
lence and consequences of resistance, as well as
compare resistance proﬁles among various drugs of the
same class.
The FDA has recommended that resistance testing
begin in preclinical development [31], with in vitro selec-
tion of resistant mutants, phenotypic and genotypic
characterization of the mutants, and cross-resistance
analyses to be completed before initiating clinical
studies in infected patients. Resistance testing should
subsequently be continued in all phases of clinical devel-
opment, and deﬁnitions of virologic failures (break-
through, relapse, nonresponse) be clearly deﬁned for
each protocol. These deﬁnitions should be standardized
across drugs of the same class and trials, but no such rig-
orous standardization is currently in place.
We agree that resistance testing, even in patients
responsive to therapy, should be a routine part of clin-
ical development (Table 2). Initial studies should use
the most sensitive techniques available, such as clonal
sequencing, with 30–80 clones analyzed oer sample
per time point. Later stage clinical trials could more
reasonably shift to a population sequencing approach.
Societal and other interested groups, along with
regulatory agencies, will need to work together to
devise meaningful guidelines that should be univer-
sally followed. Subsequent storage and sharing of
data would allow a broader understanding of the
extent and eﬀects of resistance and would provide
additional insight for modeling and prediction. Resis-
tance testing will likely become integrated into clinical
practice once direct antiviral agents are approved, as
it has for HIV and hepatitis B virus, but the need
for resistance testing outside of clinical development
is unclear at present.12. What data currently exist for retreating prior
nonresponders to PEG-IFN and RBV with direct
antivirals?
Preliminary data with telaprevir suggest that patients
who did not achieve SVR with IFN and RBV therapy
may beneﬁt from triple therapy. The data are especially
encouraging for patients who experienced breakthrough
or relapse with their prior course of therapy.
Table 2
Strategies for detecting and analyzing drug resistant HCV variants that require standardization and guideline development
Strategy
Development phase
Preclinical Identiﬁcation of resistant mutants via serial passage
Genotypic analyses
Cross-resistance analyses
Early phase clinical trials Resistance testing using clonal sequencing at pre-speciﬁed time intervals, optimally with 30–80 clones to
detect minority species
Consistent cross-study deﬁnitions of (a) virologic failure (breakthrough, relapse, nonresponse) and (b) testing
schedules
Later phase clinical trials Resistance testing using population sequencing
Clinical practice Integrate resistance testing evaluations with multiple agents and predictive models for drug sensitivity
All phases Public data storage and sharing of data
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60 previous nonresponders to PEG-IFN plus RBV from
the control arms of the PROVE studies, patients were
categorized as null responders (<1 log10 IU/mL HCV
RNA decline at week 4 or <2 log10 IU/mL by week
12), partial responders (P2 log10 IU/mL decline by
week 24), relapsers, or breakthrough patients [32]. Over-
all, 83% achieved an RVR at week 4 during retreatment.
Patients with previous breakthrough or relapse had
RVR rates of 100%, whereas those with prior null
response had RVR rates of 70% to 75%. Rates of
SVR are awaited.
PROVE 3 is also an ongoing phase 2b study evaluat-
ing telaprevir-based triple therapy in genotype 1 HCV
patients who did not achieve SVR with at least one prior
PEG-IFN and RBV regimen. At the interim analysis,
52% of patients who received 12 weeks of telaprevir with
PEG-IFN and RBV followed by 12 weeks of PEG-IFN
and RBV alone achieved SVR at 12 weeks post treat-
ment. In the various categories of prior response,
SVR12 rates were as follows: 41% for prior nonrespond-
ers, 73% for prior relapsers, and 44% for prior break-
throughs [33].
Boceprevir has also been evaluated in prior nonre-
sponders. In a phase 2, dose-ﬁnding study, boceprevir
with PEG-IFN and RBV therapy was used to treat prior
nonresponders to PEG-IFN plus RBV. Unfortunately,
the regimen yielded low SVR rates, 7–14% [21]. However,
protocol changes during the course of the trial, including a
boceprevir dose increase, limit the interpretation of the
data, and further deﬁnitive ongoing studies are underway
with this agent in the nonresponder setting.13. For patients who have received a direct antiviral agent
alone, should triple therapy with that agent and PEG-IFN
and RBV be considered?
There is modest evidence that some patients who
experience viral breakthrough during telaprevir mono-therapy can subsequently respond to telaprevir in com-
bination with PEG-IFN plus RBV [25], but the long-
term sustained response rates are unknown (see conse-
quences of resistance, above).
It is also unknown whether the same holds true for
other direct antiviral agents. Because the antiviral treat-
ment paradigm now includes therapy with PEG-IFN
and RBV, patients receiving monotherapy represent a
minority, yet because of such patients, this question
remains important and must be addressed in clinical tri-
als in the near future.14. What options are available for patients who have
failed to achieve a sustained virologic response with direct
antiviral-based regimens?
One option is to attempt a triple therapy regimen that
includes an alternate antiviral, although the issues of re-
emergence of resistance need to be considered carefully,
especially in re-exposing patients to agents of same class.
There is a need for well-designed clinical trials to inves-
tigate this area now. Frequent monitoring with sensitive
molecular techniques will be needed to detect the emer-
gence of resistant variants. Combination therapy with
multiple direct antivirals (such as combining protease
and polymerase inhibitors) is an alternate strategy that
may be eﬀective for patients who fail ‘‘triple” therapy.
Again, resistance will be an important issue, and no such
data on these regimens is currently available.15. How will the presence of viral variants aﬀect long-term
virologic response?
Data from long-term follow-up of sustained respond-
ers to IFN plus RBV therapy suggest that at 5 years
after treatment, the vast majority of patients, approxi-
mately 99%, remain HCV RNA negative and are con-
sidered cured and have no clinically related outcomes
192 A. Thompson et al. / Journal of Hepatology 50 (2009) 184–194of note [34]. However, IFN and RBV do not induce spe-
ciﬁc viral variants and are thus unlikely to result in vari-
ants that have a potential long-term consequence. As
described above, telaprevir withdrawal removes the
selection pressure for viral variants [30], yet we cannot
exclude a long-term eﬀect of harboring resistant vari-
ants. Thus, long-term follow-up studies evaluating dis-
ease progression, relative ﬁtness of variants over time,
eﬀects of various classes of direct antivirals, and re-
exposure, as well as retreament outcomes, are needed.
Shared databases and registries will be required to eval-
uate these issues critically.Fig. 3. Getting from A to B to C for treating chronic HCV infection in
the next decade. With speciﬁcally targeted antivirals expected to enter
the market in the next 5 years, sustained virologic response (SVR) rates
in HCV genotype 1 patients will likely increase from 40% currently with
pegylated interferon (PEG-IFN) and ribavirin (RBV) to approximately
60% or more with a targeted antiviral and PEG-IFN and RBV (with or
without a shortened duration of therapy). Relapse rates are expected to
decline, as they have been documented to in trials to date, although rates
of discontinuation may well increase because of the increased risk of
adverse eﬀects with triple therapy. In the more distant future, higher
response rates will hopefully be achieved, theoretically, by multiple drug
regimens that limit discontinuation rates, enhance eﬃcacy and tolerabil-
ity, and with some possible small enhancement in relapse and nonre-
sponder (NR) rates, as shown.16. What are the weaknesses and exigencies of the current
direct antiviral trials?
As discussed elsewhere in this review, the published
data so far are limited, reﬂecting the current early stage
of drug development in this therapeutic area. Early
phase studies to date have been heterogeneous in design,
included small numbers of patients, and there has been a
lack of standardization of resistance testing between dif-
ferent trials and drugs, making generalizability and
development of themes or principles diﬃcult. For exam-
ple, the beneﬁt of lead-in pegIFN and RBV will need to
be assessed for individual agents and diﬀerent patient
populations. In addition, the optimal duration of a three
drug combination therapy, the duration of pegIFN and
RBV ‘‘consolidation”, and the most eﬀective doses of
pegIFN and RBV that maximize response must be clar-
iﬁed in future trial designs. Studies using combinations
of direct antivirals of diﬀerent classes must also be
urgently performed. Other patient populations will need
to be evaluated, including patients with non-genotype 1
infection, as well as ‘diﬃcult-to-treat’ populations most
in need of more eﬃcacious therapies (such as post-liver
transplant HCV-infected patients, those with decompen-
sated liver disease, renal failure or HIV co-infection).
These and other issues will need to be addressed sooner,
rather than later in clinical development.17. Ideally, how should therapy look in 5 or 10 years time?
In 5 years, it is likely that the ﬁrst direct antivirals will
be approved for use in combination with PEG-IFN and
RBV for HCV patients. Based on existing data, we can
predict that combination triple therapy will increase
SVR rates in HCV genotype 1 patients from 40% to
approximately 60%, or more (Fig. 3). At the same time,
relapse rates should decline to 5–10%. Although treat-
ment duration may be shortened for a proportion of
patients, rates of discontinuation may well increase
because of the increased risk of side eﬀects with triple
therapy.In 10 years, the treatment landscape will almost cer-
tainly look very diﬀerent, with speciﬁcally targeted
antivirals a regular component of treatment regimens.
Combination therapy with two or more antivirals and
PEG-IFN may replace triple therapy with an antiviral,
PEG-IFN, and RBV. If multiple antivirals are available
in the marketplace, treatment decisions regarding com-
bination therapies and retreatment options may become
increasing complex, especially with the background of
resistance.
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